SteriLance Medical's New Pen Needle Design Prioritizes Stability & User Comfort

NEW YORK, NY – November 03, 2025 – SteriLance Medical’s Sandstone brand is introducing a new iteration of its pen needle, the Easydrip™ Plus, featuring its proprietary Hextra Tech™ hexagonal hub. The company believes this innovation will address a key need in diabetes self-care: a more stable and comfortable injection experience. While the pen needle market is crowded, SteriLance is positioning itself as a user-focused player with a focus on incremental improvements that can meaningfully impact patient adherence.

Addressing a Need for Stability

The global diabetes epidemic continues to drive demand for effective and convenient insulin delivery solutions. With over 537 million adults living with diabetes worldwide, even small improvements in injection technique and patient comfort can have a significant ripple effect on health outcomes. The Easydrip™ Plus pen needle, incorporating the Hextra Tech™ hub, aims to reduce injection instability – a common concern for self-injectors. “For many patients, the anxiety surrounding injections is as much about the how as it is about the medication itself,” noted one endocrinologist who wished to remain anonymous. “Anything that can instill confidence and reduce discomfort is a welcome development.”

The Hextra Tech™ hub is designed with a broad, six-facet platform engineered to minimize wobble and bending during insertion. Recent studies conducted at the University of Shanghai for Science and Technology (USST) demonstrated a significant reduction in needle deformation and improved anti-tilt resistance when compared to conventional narrow-hub needles. These findings suggest that the new design can contribute to a more consistent and accurate subcutaneous delivery of insulin.

Competition in a Mature Market

The pen needle market is a multi-billion dollar industry dominated by established players like Becton Dickinson and Novo Nordisk. These companies benefit from brand recognition, extensive distribution networks, and a wide range of products. However, SteriLance Medical is carving out a niche by focusing on user-centered design and human-factors engineering. “The market is competitive, undoubtedly,” says an industry analyst. “But there’s always room for innovation, especially when it addresses a specific pain point for patients.”

The company’s strategy hinges on offering a practical alternative to the premium brands and lower-cost generics. The Easydrip™ Plus combines features designed for both comfort and ease of use, including enlarged caps for secure handling and a thin-wall, polished cannula with silicone lubrication. SteriLance Medical recently acquired FDA registration and adheres to stringent quality standards, including ISO 13485 certification and compliance with the Medical Device Regulation (MDR) 2017/745. While larger players such as BD and Novo Nordisk have robust research and development budgets, SteriLance is betting that focused innovation can create value.

The global pen needle market is projected to reach USD 7.8 billion by 2030, driven by the rising prevalence of diabetes and an increasing demand for self-injection devices. Recent market analysis points to a growing preference for shorter needle lengths and safety features, further highlighting the need for innovative solutions like the Easydrip™ Plus.

Beyond the Hub: A Focus on Patient Empowerment

The introduction of the Easydrip™ Plus pen needle is part of a broader trend towards patient empowerment in diabetes care. Patients are increasingly demanding more control over their health and seeking technologies that can help them manage their condition more effectively. This push for personalized medicine is driving innovation in areas such as continuous glucose monitoring, insulin pumps, and smart injection devices.

“The focus is shifting from simply delivering medication to providing a holistic solution that supports the patient’s lifestyle and empowers them to take ownership of their health,” explains a diabetes care specialist. “Innovations like the Easydrip™ Plus, while seemingly small, can make a big difference in terms of patient confidence and adherence.”

The Hextra Tech™ hub, with its emphasis on stability and comfort, is designed to alleviate some of the anxieties associated with self-injection. By reducing the risk of wobble and bending, the new design can help patients feel more confident and in control. Moreover, the Easydrip™ Plus features enlarged caps that make it easier to handle, particularly for individuals with limited dexterity. The company holds over 200 patents globally related to blood-sampling and injection solutions, showing a commitment to IP and innovation. SteriLance Medical’s strategy is to build on its strengths in human-factors engineering and focus on developing solutions that address the specific needs of diabetes patients.